Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
Altimmune (Nasdaq: ALT) has appointed Greg Weaver as Chief Financial Officer, effective immediately. Weaver brings over 25 years of finance experience in life sciences companies and will lead the company's finance, accounting, and investor relations functions. His previous role was CFO at Cognito Therapeutics, and he notably led a $225 million IPO at atai Life Sciences. Throughout his career, Weaver has managed various capital market transactions and served as CFO at multiple biotech companies, including Sirna Therapeutics and ILEX Oncology. The appointment comes at a important time as Altimmune advances its lead program, pemvidutide, which targets metabolic disorders through liver-targeting mechanisms.
Altimmune (Nasdaq: ALT) ha nominato Greg Weaver come Chief Financial Officer, con effetto immediato. Weaver porta con sé oltre 25 anni di esperienza finanziaria nel settore delle scienze della vita e guiderà le funzioni finanziarie, contabili e di relazioni con gli investitori dell'azienda. Il suo ruolo precedente era CFO presso Cognito Therapeutics, e ha guidato un'IPO da 225 milioni di dollari presso atai Life Sciences. Nel corso della sua carriera, Weaver ha gestito diverse transazioni nei mercati dei capitali ed è stato CFO in numerose aziende biotecnologiche, tra cui Sirna Therapeutics e ILEX Oncology. Questa nomina arriva in un momento importante, poiché Altimmune accelera il suo programma principale, il pemvidutide, che mira a trattare i disturbi metabolici attraverso meccanismi mirati al fegato.
Altimmune (Nasdaq: ALT) ha nombrado a Greg Weaver como Director Financiero, con efecto inmediato. Weaver aporta más de 25 años de experiencia financiera en empresas de ciencias de la vida y liderará las funciones de finanzas, contabilidad y relaciones con inversores de la compañía. Su rol anterior fue CFO en Cognito Therapeutics, y notablemente lideró una OPI de 225 millones de dólares en atai Life Sciences. A lo largo de su carrera, Weaver ha gestionado varias transacciones en los mercados de capital e ha sido CFO en múltiples empresas biotecnológicas, incluyendo Sirna Therapeutics e ILEX Oncology. Esta nombramiento llega en un momento importante, ya que Altimmune avanza en su programa principal, el pemvidutide, que apunta a trastornos metabólicos a través de mecanismos dirigidos al hígado.
Altimmune (Nasdaq: ALT)는 Greg Weaver를 최고재무책임자(CFO)로 즉시 임명했습니다. Weaver는 생명과학 회사에서 25년 이상의 금융 경험을 보유하고 있으며 회사의 재무, 회계 및 투자자 관계 기능을 이끌 것입니다. 그의 이전 역할은 Cognito Therapeutics의 CFO였으며, atai Life Sciences에서 2억 2천 5백만 달러 규모의 IPO를 이끌었습니다. 그의 경력 동안 Weaver는 다양한 자본 시장 거래를 관리했으며, Sirna Therapeutics와 ILEX Oncology를 포함한 여러 생명공학 회사의 CFO로 활동했습니다. 이 임명은 Altimmune이 간표적 기전을 통해 대사 장애를 겨냥한 주요 프로그램 pemvidutide를 발전시키고 있는 중요한 시점에 이루어졌습니다.
Altimmune (Nasdaq: ALT) a nommé Greg Weaver au poste de Directeur Financier, avec effet immédiat. Weaver possède plus de 25 ans d'expérience financière dans des entreprises de sciences de la vie et dirigera les fonctions de finance, de comptabilité et de relations investisseurs de la société. Avant cela, il était CFO chez Cognito Therapeutics et a notamment dirigé une introduction en bourse de 225 millions de dollars chez atai Life Sciences. Au cours de sa carrière, Weaver a géré plusieurs transactions sur les marchés de capitaux et a occupé le poste de CFO dans plusieurs entreprises biopharmaceutiques, y compris Sirna Therapeutics et ILEX Oncology. Cette nomination intervient à un moment clé, alors qu'Altimmune fait progresser son programme phare, le pemvidutide, qui cible les troubles métaboliques par le biais de mécanismes spécifiques au foie.
Altimmune (Nasdaq: ALT) hat Greg Weaver mit sofortiger Wirkung zum Chief Financial Officer ernannt. Weaver bringt über 25 Jahre Erfahrung im Finanzwesen in Unternehmen der Lebenswissenschaften mit und wird die Finanz-, Buchhaltungs- und Investor-Relations-Funktionen des Unternehmens leiten. In seiner vorherigen Position war er CFO bei Cognito Therapeutics und hat bemerkenswerterweise einen Börsengang in Höhe von 225 Millionen Dollar bei atai Life Sciences geleitet. Im Laufe seiner Karriere hat Weaver zahlreiche Kapitalmarkttransaktionen verwaltet und war CFO mehrerer Biotechnologieunternehmen, einschließlich Sirna Therapeutics und ILEX Oncology. Die Ernennung erfolgt zu einem wichtigen Zeitpunkt, da Altimmune sein Hauptprogramm, pemvidutide, vorantreibt, das auf Stoffwechselstörungen durch leberspezifische Mechanismen abzielt.
- Appointment of seasoned CFO with 25+ years of life sciences finance experience
- New CFO has successful track record in capital raising, including $225M IPO
- Strong experience in M&A transactions and public company operations
- None.
GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), effective immediately. Mr. Weaver will lead the Company’s finance and accounting functions, including SEC reporting and investor relations.
“We are pleased to welcome Greg to Altimmune’s executive team during such a pivotal time in our evolution. He has a wealth of experience that we believe will be invaluable as we enter a crucial period in the development of our lead program, pemvidutide and in our advancement as an organization,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “We look forward to his contributions and are excited for the opportunity to leverage his expertise and broad industry relationships as we continue working to build value through the advancement of pemvidutide.”
“Pemvidutide is a unique and highly promising product candidate with broad therapeutic potential spanning a variety of metabolic disorders for which its direct liver targeting mechanism and robust lipid lowering capabilities can be beneficial,” added Mr. Weaver. “The data generated to-date in obesity and liver disease are extremely encouraging, and with multiple significant milestones on the horizon I am excited to play a role in Altimmune’s future success.”
Mr. Weaver joins Altimmune with over 25 years of finance experience across a range of publicly-traded and privately-held life sciences companies. Most recently, he was CFO of Cognito Therapeutics, a clinical-stage company targeting neurodegenerative diseases. Prior to joining Cognito, he was CFO at atai Life Sciences (Nasdaq: ATAI), a neuropsychiatry company where he led a
Earlier in his career, he served as CFO at multiple publicly-traded biotech companies including Sirna Therapeutics, a genetic medicines company acquired by Merck and ILEX Oncology, a commercial-stage company acquired by Genzyme.
He currently serves as a Director and Chair of the Audit Committee at BioIntelliSense, a commercial-stage patient monitoring technology company, Director and Audit Committee Chair at Centenara Labs (formerly Rejuveron), a clinical-stage biopharma company focused on the science of aging and a Director at HarborPath, a non-profit organization focused on providing patients with access to life-saving medications. A United States Air Force veteran, he holds a bachelor’s degree in Accounting and Finance from Trinity University and an MBA from Boston College.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Forward-Looking Statement
Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the timing of key milestones for our clinical assets, and the prospects for the utility of, regulatory approval, commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Altimmune, Inc. may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks relating to: delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company’s product candidates; the Company’s ability to manufacture clinical trial materials on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company’s business, financial conditions and results of operations are contained in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors” in the Company’s most recent annual report on Form 10-K and our other filings with the SEC, which are available at www.sec.gov.
Company Contact:
Vipin Garg
President and Chief Executive Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
This press release was published by a CLEAR® Verified individual.
FAQ
Who is the new CFO of Altimmune (ALT)?
What is Greg Weaver's previous experience before joining Altimmune (ALT)?
What will be Greg Weaver's responsibilities at Altimmune (ALT)?
What is Altimmune's (ALT) lead program mentioned in the announcement?
